Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance board adds Slater

Executive Summary

Former HHS Assistant Secretary for Health Eve Slater has joined Theravance's board of directors, the firm announced Dec. 12. Before joining HHS, Slater was Merck VP-external policy & public affairs. Slater rejoins former Merck CEO and current Theravance Chairman Roy Vagelos on the board. Slater serves on the boards of a number of other firms, including Vertex and VaxGen (1"The Pink Sheet" July 18, 2005, In Brief)...

You may also be interested in...



Ex-HHS official joins VaxGen board

Eve Slater joins VaxGen board of directors. Slater served as assistant secretary for health and chief policy advisor to former HHS Secretary Tommy Thompson. Before joining HHS, she was Merck's VP-external policy & public affairs. Slater also serves on the board of data management solutions firm Phase Forward and Vertex Pharmaceuticals (1"The Pink Sheet" June 27, 2005, In Brief)...

QUOTED. 25 February 2021. Adam Saltman.

A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.

Daiichi's Novel EZH Candidate Moves Ahead With New Consortium Trial

Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.

Topics

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel